4886
ASKA Pharmaceutical Holdings Co.,Ltd.
あすか製薬ホールディングス
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
56,607
Mar 2023
60,461
Mar 2024
62,843
Mar 2025
64,139
Mar 2026
71,127
Operating profit(million JPY)
Mar 2022
4,795
Mar 2023
5,108
Mar 2024
6,500
Mar 2025
5,331
Mar 2026
5,834
Operating profit margin(%)
Mar 2022
8.47
Mar 2023
8.45
Mar 2024
10.34
Mar 2025
8.31
Mar 2026
8.2
Profit before tax(million JPY)
Mar 2022
6,163
Mar 2023
5,357
Mar 2024
9,862
Mar 2025
6,192
Mar 2026
6,991
Profit(million JPY)
Mar 2022
4,290
Mar 2023
4,238
Mar 2024
7,545
Mar 2025
5,101
Mar 2026
5,424
Total assets(million JPY)
Mar 2022
83,297
Mar 2023
87,138
Mar 2024
90,745
Mar 2025
100,534
Mar 2026
112,379
Cash and cash equivalents(million JPY)
Mar 2022
17,103
Mar 2023
17,505
Mar 2024
16,738
Mar 2025
10,603
Mar 2026
10,126
Cash flows from operating activities(million JPY)
Mar 2022
2,842
Mar 2023
3,351
Mar 2024
1,486
Mar 2025
2,485
Mar 2026
6,303
Cash flows from investing activities(million JPY)
Mar 2022
6,743
Mar 2023
-1,126
Mar 2024
1,706
Mar 2025
-6,124
Mar 2026
-5,752
Cash flows from financing activities(million JPY)
Mar 2022
-2,996
Mar 2023
-1,820
Mar 2024
-3,943
Mar 2025
-2,956
Mar 2026
-818
Return on equity(%)
Mar 2022
8.77
Mar 2023
8.2
Mar 2024
12.96
Mar 2025
8.02
Mar 2026
8
Equity ratio(%)
Mar 2022
58.7
Mar 2023
62.58
Mar 2024
68.25
Mar 2025
64.96
Mar 2026
62.61
Earnings per share(JPY per share)
Mar 2022
151.22
Mar 2023
150.08
Mar 2024
266.51
Mar 2025
179.95
Mar 2026
191.12
Net assets per share(JPY per share)
Mar 2022
1,734.8
Mar 2023
1,928.14
Mar 2024
2,186.1
Mar 2025
2,302.61
Mar 2026
2,477.81
Dividend per share(JPY per share)
Mar 2022
15
Mar 2023
16
Mar 2024
40
Mar 2025
55
Mar 2026
60
Payout ratio(%)
Mar 2022
9.92
Mar 2023
10.66
Mar 2024
15.01
Mar 2025
30.56
Mar 2026
31.39
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.